Aberrant methylation of tumor suppressor genes in patients with refractory anemia with ring sideroblasts.
This study evaluates the incidence and prognostic impact of aberrant methylation of 25 tumor suppressor genes in 40 patients with RARS, a MDS subtype, by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay. Methylation of at least one gene was detected in 18 patients (45%). The genes methylated were CDKN2B (20%), RASSF1 (18%), RARB (10%), CDH13 (7.5%) and FHIT (5%). Patients with at least one methylated gene had a significantly shorter OS than patients without methylated genes. Aberrant methylation is a frequent event in patients with RARS as in patients with high-risk MDS appears to confer a worse prognosis.
Valencia
Ana
A
Department of Hematology, Hospital Universitario La Fe, Avda. Campanar 21, 46009 Valencia, Spain. valencia ana@gva.es
Cervera
José
J
Such
Esperanza
E
Ibañez
Mariam
M
Gómez
Inés
I
Luna
Irene
I
Senent
Leonor
L
Oltra
Silvestre
S
Sanz
Miguel A
MA
Sanz
Guillermo F
GF
D017766:Acid Anhydride Hydrolases / Q000235:genetics; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000753:Anemia, Refractory / Q000235:genetics*; D000756:Anemia, Sideroblastic / Q000235:genetics*; D050762:Cyclin-Dependent Kinase Inhibitor p15 / Q000235:genetics; D019175:DNA Methylation; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009363:Neoplasm Proteins / Q000235:genetics; D016133:Polymerase Chain Reaction; D011379:Prognosis; D018168:Receptors, Retinoic Acid / Q000235:genetics; D025521:Tumor Suppressor Proteins / Q000235:genetics*; D000099170:Bis(5'-adenosyl)triphosphatase
D017766:Acid Anhydride Hydrolases; D050762:Cyclin-Dependent Kinase Inhibitor p15; D009363:Neoplasm Proteins; D018168:Receptors, Retinoic Acid; D025521:Tumor Suppressor Proteins; D000099170:Bis(5'-adenosyl)triphosphatase; C493966:CDKN2B protein, human; C411762:RASSF1 protein, human; C082925:retinoic acid receptor beta